Figure 4. HO-1 inhibition increases the sensitivity of leukemic cells to TKIs in BCR-ABL1⁺-IK6 patients.

Cell viability was determined by MTT assay after 48 hours’ incubation. The IC50 mean and SD of primary leukemic cells from 3 patients in each group were shown in the tables. A. Primary CD34⁺ leukemic cells (4×10⁴ cells per well) were treated with different doses of imatinib (15nM,75nM,100nM, 200nM, 400nM, 600nM, 800nM, 1000nM) for 48 h. B. BCR-ABL1⁺-IK6 leukemic cells (IK6), IK6/siHO-1 and IK6/vector’ were incubated with different concentration of imatinib as indicated above. C. Equal numbers of IK6, IK6/siHO-1, IK6/vector’ were incubated with different concentration of nilotinib (8nM, 12nM, 24nM, 48nM, 96nM). D. Cells were treated with 10uM ZnPPIX and differrant concentration of imtinib as indicated above.